Connect with us

Cannabis News

Trump ‘Supports’ Hemp THC Ban That’s Advancing In Senate, White House Says

Published

on

President Donald Trump “endorses it.” He proposed banning THC-containing hemp products included in the Senate spending billA White House spokesman says cannabis, alcohol and other interests are continuing efforts to influence the final deal.

A day after the Senate passed the debt relief package – with provisions that would effectively wipe out the market for hemp operators – a White House staffer told NBC News that the president “supports the current language in the hemp bill.”

While Trump endorsed cannabis reform on the campaign trail (including a pending marijuana redistricting proposal), he has also expressed concern about the non-medical use of cannabis. In his first term, he signed the 2018 Farm Bill that federally legalized hemp and its derivatives, but has been less vocal on issues related to cannabis’ cousin.

Now, eager for a plan to reopen the government amid a historic shutdown, the White House says it stands by the controversial ban, which is just one part of a larger legislative package.

Marijuana Moments reached out to the White House for additional comment, but a representative was not immediately available.

Meanwhile, Sen. Rand Paul (R-KY) hasn’t thrown in the towel yet, introducing an amendment calling for the leader to crack down on hemp language altogether.

But there are many competing voices on the issue, including a coalition of alcohol companies that sent a letter to senators Monday urging them to back the current language.

The American Distilled Spirits Alliance (ADSA), the Beer Institute (BI), the Distilled Spirits Council of the United States (DISCUS), Wine America and the Wine Institute said in the letter that Paul’s “short-sighted actions could threaten the delicately balanced deal to reopen the federal government.”

“Producers of alcoholic beverages, one of the most highly regulated consumer products, are calling on the Senate to reject Senator Paul’s attempts to allow hemp-derived THC products to be sold across the country without federal regulation and oversight,” it says. “We stand ready to work with Congress and the Administration to enact meaningful regulations that protect consumers and ensure a safe and orderly marketplace for these toxic products when this loophole is addressed.”

The alcohol companies individually pushed the Congress stand on the hemp ban in a letter to the leader last week.

Under current law, cannabis products are considered legal hemp if they contain less than 0.3 percent delta-9 THC by dry weight.

The new legislation specifies that, within a year of taking effect, the weight will be applied to all THC—including delta-8 and other isomers. Also, “as tetrahydrocannabinol (or any other marketed cannabinoid) with similar effects in humans or animals (as determined by the Secretary of Health and Human Services).”

The new definition of legal hemp would also prohibit “any hemp-derived cannabinoid intermediate product marketed or sold as an end product or directly to an end consumer for personal or household use,” as well as products containing cannabinoids that are synthesized or manufactured outside of the cannabis plant or that cannot be produced naturally by the plant.

Legal hemp products would be limited to a total of 0.4 milligrams of total THC or any other cannabinoid with similar effects per container.

Within 90 days of the bill’s passage, the Food and Drug Administration (FDA) and other agencies would be required to “publish a list of all cannabinoids known to FDA to be naturally produced by a Cannabis sativa L. plant, as reflected in the peer-reviewed literature,” “all tetrahydrocannabinol classes known to be plants of the cannabinoid class known” and “all cannabinoids” known to occur naturally. Cannabinoids that have or are marketed as having effects similar to cannabinoids of the tetrahydrocannabinol class.”

The language differs slightly from provisions in legislation advanced out of the House and Senate Appropriations panels, which would have banned products with “quantifiable” amounts of THC, to be determined by the HHS secretary and the agriculture secretary.

Separately, the newly released appropriations legislation omits language passed by the House earlier this year. let VA doctors recommend medical cannabis to their military veteran patients in states where it is legal.

The appropriations bill’s progress comes amid a push by parties on both sides of the hemp debate as they negotiate a deal to influence Congress.

For example, last week more than 50 alcohol distributors have come together Oppose efforts in Congress to ban hemp products containing THCinsisting to lawmakers that as demand for alcohol has “declined”, the cannabis market has helped sustain their industry.

It is interesting that there is a special distribution among the agents of alcohol, many of them have reported lobbying on hemp issues this year. There seems to be disagreement on the way forward between the wholesalers that distribute alcohol and hemp products and the big brands that market their drinks.

A major consumer trade association, its member corporations include Coca-Cola, General Mills, Kraft Heinz and Nestlé. Pressuring Congress to ban THC-containing hemp products.

Meanwhile, a bipartisan group of 39 state and territory attorneys general recently petitioned Congress. clarifying the federal definition of hemp and imposing regulations preventing the sale of intoxicating cannabinoid products.

Minnesota Attorney General Keith Ellison (D), who helped write that letter to congressional leaders last month, he defended his decision amid criticism from industry players and advocates He questioned why attorneys general in states with strong hemp markets like Minnesota would promote federal recriminalization of those products.

Two GOP lawmakers—Sen. Mitch McConnell (R-KY) Rep. Andy Harris (R-MD)—has committed to a complete ban on THC-containing hemp products. But others like Paul have insisted that such a policy change would destroy the industry. And Paul had warned before that he would go far stick to large-scale spending legislation if the entire ban is kept intact.

The senator also pushed back against a recent letter from state and territory attorneys general imploring Republican leaders to completely prevent the marketing of intoxicating hemp products.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

As for legislative opportunities, Paul recently ran for the legislature This requires a study and report on the state’s regulatory models for hemp It could inform future revisions to the federal law—rather than outright banning sales, as McConnell wanted.

In August, McConnell – who pushed for federal hemp legalization under the 2018 Farm Bill – took to the Senate floor. criticized those who opposed the ban, including Paul.

Meanwhile, Paul recently introduced a stand-alone bill that would go in the opposite direction of the hemp ban, proposing to triple the concentration of THC that the crop could legally containaddressing several other concerns expressed by industry about federal regulations.

The senator introduced legislation in June called the Hemp Economic Mobilization Plan (HEMP) Act. It reflects versions backed up in recent sessions.

read it the letter Alcohol companies below on the proposed hemp ban:

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

Tilray Medical announces commercial launch of medical cannabis in Panama

Published

on

By

Tilray Medical has announced the launch of its first medical cannabis product in Panama, part of the company’s continued global expansion and commitment to improving patient access to pharmaceutical grade cannabinoids worldwide.

Following the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP certified production facilities in Portugal through a joint venture with Solana Life Group S. de RL, the Product is to be distributed through Farmacias Arrocha, one of the leading pharmaceutical chains in Panama, where patients will be able to access Tilray Oral Solution CBD with medical prescription100. This is expected to provide patients and healthcare professionals with access to regulated medical cannabis of pharmaceutical quality through established healthcare channels.

Rajnish Ohri, International President, Tilray Brands, said: “At Tilray Medical, we believe that every patient deserves access to safe, consistent, pharmaceutical-grade cannabis products. The launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines around the world. We want pharmacists and patients to help shape the future of responsible access, advance medical education and provide high-quality treatment options that improve lives.”

The launch supports the Panamanian medical cannabis framework established by Law 242 of 2021 and follows important regulatory advances made by the Ministry of Health, including No. 0406 of May 12, 2026. The decision, which established the main conditions for the admission of patients. The Ministry also recently introduced the System for the Identification of Medical Cannabis Users and Authorized Caregivers (SIUCMAA), creating a structured way to authorize medical practitioners and register patients.

Manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use in patients with qualified medical conditions permitted under Panamanian law, where permitted. The products reflect Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.

Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP certified medical cannabis products to regulated markets worldwide. The platform enables Tilray Medical to effectively support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.

For more information:
Tilray
www.tilray.com

Continue Reading

Cannabis News

Medical Marijuana Is ‘Effective’ In Providing Relief To Patients With Restless Legs Syndrome, Study Shows

Published

on

By

People with restless leg syndrome (RLS) may find “significant” long-term relief with cannabis treatment, according to a new study.

While dopamine agonists have traditionally been the “first-line treatment” for RLS, recent studies indicate that gabapentinoids are now being recommended, the researchers said. Because cannabinoids, like gabapentinoids, inhibit a certain type of amino acid associated with the disorder, scientists decided to test their therapeutic effectiveness.

The open-label exploratory study, conducted by European researchers at the University of Madrid and published in the Journal of Neurology, found that a cannabis product containing 2.7 mg of THC and 2.5 mg of CBD was “effective in reducing RLS severity” among patients with multiple sclerosis and “associated idiopathic RLS.”

“Improvements were observed after 1 to 3 months of treatment and were maintained after 1 year among patients who continued therapy,” the study of 18 patients with RLS showed. For those who remained in treatment after a year, 67 percent “continued to show sustained improvement.”

The the findings it may not be surprising that cannabis in particular is known to reduce the severity of muscle spasms and related conditions, but its effectiveness for RLS is remarkable given that no state specifically lists it as a condition for medical cannabis.

Of course, RLS can be a symptom of other general disorders like multiple sclerosis, and some states give doctors more latitude to make recommendations for medical marijuana for any condition they see fit.

In any case, research outside of Spain could be based on research into alternative treatment options that could replace dopamine agonists in the treatment of restless legs syndrome.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Wyoming AG keeps cannabis on Schedule I, rejects federal reclassification

Published

on

By











Wyoming Attorney General Keith Kautz announced on July 7 that he would keep all marijuana products in Schedule I of Wyoming’s Controlled Substances Act, refusing to align the state’s cannabis policy with the federal reorganization order issued earlier this year.

Kautz, who also serves as Wyoming’s drug and substance abuse commissioner, held a public hearing on June 18 after filing an objection to aligning the state’s cannabis schedule with a federal amendment on May 27. State law requires the commissioner to give interested parties an opportunity to be heard after that objection, but only nine people responded. Four email comments supported leaving cannabis as a Schedule I drug, four as Schedule III. It was approved for use and one person attended the hearing to request that cannabis remain in Schedule I.

His decision follows an April 2026 order signed by U.S. Attorney General Todd Blanche that bans state-licensed medical cannabis, FDA-approved cannabis products, cannabis extracts and naturally derived delta-9 THC III.

Kautz’s office says: “After consideration of all stakeholder comments, the commissioner has determined that all marijuana products, including marijuana subject to the state’s medical marijuana license, will remain in Schedule I of the Wyoming Controlled Substances Act.”

His announcement adds, “The decision to reschedule medical marijuana and marijuana products is an important policy decision that is best left to the Wyoming Legislature and should not be made through administrative rule.”

Wyoming remains one of eight states without a medical cannabis program. A December 2020 poll by the University of Wyoming’s Wyoming Center for Polling and Analysis found that 85 percent of state residents support legalizing medical cannabis, despite a failed 2024 ballot initiative effort. Possession of three ounces or less carries up to 12 months in prison under current state law, and selling any amount is punishable by up to 10 years in prison and a $10,000 fine.

Kautz says his office will “properly schedule products approved by the United States Food and Drug Administration once that agency has approved the product,” pointing to the Schedules II and III listings of Cesamet and Dronabinol as evidence that the state complies with federal cannabinoid drug law.










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media